Literature DB >> 33010290

The road to restore vision with photoreceptor regeneration.

Chang-Jun Zhang1, Ya Ma2, Zi-Bing Jin3.   

Abstract

Neuroretinal diseases are the predominant cause of irreversible blindness worldwide, mainly due to photoreceptor loss. Currently, there are no radical treatments to fully reverse the degeneration or even stop the disease progression. Thus, it is urgent to develop new biological therapeutics for these diseases on the clinical side. Stem cell-based treatments have become a promising therapeutic for neuroretinal diseases through the replacement of damaged cells with photoreceptors and some allied cells. To date, considerable efforts have been made to regenerate the diseased retina based on stem cell technology. In this review, we overview the current status of stem cell-based treatments for photoreceptor regeneration, including the major cell sources derived from different stem cells in pre-clinical or clinical trial stages. Additionally, we discuss herein the major challenges ahead for and potential new strategy toward photoreceptor regeneration.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Delivery strategy; Neuroretinal diseases; Photoreceptor; Regeneration; Stem cell

Mesh:

Year:  2020        PMID: 33010290     DOI: 10.1016/j.exer.2020.108283

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  8 in total

Review 1.  Effects and Prognosis of Cataract Surgery in Patients with Retinitis Pigmentosa.

Authors:  Hailong He; Hao Song; Xiaodie Meng; Kai Cao; Yi-Xin Liu; Jinda Wang; Xiuhua Wan; Zi-Bing Jin
Journal:  Ophthalmol Ther       Date:  2022-09-04

2.  Functional microglia derived from human pluripotent stem cells empower retinal organ.

Authors:  Mei-Ling Gao; Xiao Zhang; Fang Han; Jia Xu; Si-Jian Yu; Kangxin Jin; Zi-Bing Jin
Journal:  Sci China Life Sci       Date:  2022-04-22       Impact factor: 10.372

3.  Systemic taurine treatment affords functional and morphological neuroprotection of photoreceptors and restores retinal pigment epithelium function in RCS rats.

Authors:  Ana Martínez-Vacas; Johnny Di Pierdomenico; Alejandro Gallego-Ortega; Francisco J Valiente-Soriano; Manuel Vidal-Sanz; Serge Picaud; María Paz Villegas-Pérez; Diego García-Ayuso
Journal:  Redox Biol       Date:  2022-10-14       Impact factor: 10.787

Review 4.  Patient iPSC-derived retinal organoids: Observable retinal diseases in-a-dish.

Authors:  Xiao-Hui Zhang; Zi-Bing Jin
Journal:  Histol Histopathol       Date:  2021-01-22       Impact factor: 2.303

5.  Co-grafts of Human Embryonic Stem Cell Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerate Royal College of Surgeons Rats.

Authors:  Biju B Thomas; Bin Lin; Juan Carlos Martinez-Camarillo; Danhong Zhu; Bryce T McLelland; Gabriel Nistor; Hans S Keirstead; Mark S Humayun; Magdalene J Seiler
Journal:  Front Neurosci       Date:  2021-10-26       Impact factor: 4.677

6.  Systemic immunosuppression promotes survival and integration of subretinally implanted human ESC-derived photoreceptor precursors in dogs.

Authors:  Ana Ripolles-Garcia; Natalia Dolgova; M Joseph Phillips; Svetlana Savina; Allison L Ludwig; Sara A Stuedemann; Uchenna Nlebedum; John H Wolfe; Oliver A Garden; Arvydas Maminishkis; Juan Amaral; Kapil Bharti; David M Gamm; Gustavo D Aguirre; William A Beltran
Journal:  Stem Cell Reports       Date:  2022-07-28       Impact factor: 7.294

Review 7.  Advances in cell therapies using stem cells/progenitors as a novel approach for neurovascular repair of the diabetic retina.

Authors:  Judith Lechner; Reinhold J Medina; Noemi Lois; Alan W Stitt
Journal:  Stem Cell Res Ther       Date:  2022-07-30       Impact factor: 8.079

8.  Ginkgo biloba Extract Attenuates Light-Induced Photoreceptor Degeneration by Modulating CAV-1-Redoxosome Signaling.

Authors:  Ke Wang; Yuan Chen; Xue Zhu; Wenjun Zou; Fanfan Zhou
Journal:  Antioxidants (Basel)       Date:  2022-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.